Aratana Therapeutics (PETX) Stock Price Down 26.6%

Acadian Asset Management LLC lifted its position in Aratana Therapeutics by 69.8% during the 3rd quarter. Acadian Asset Management LLC now …

Aratana Therapeutics logoShares of Aratana Therapeutics Inc (NASDAQ:PETX) were down 26.6% during mid-day trading on Friday . The company traded as low as $4.11 and last traded at $4.37. Approximately 6,797,889 shares changed hands during mid-day trading, an increase of 411% from the average daily volume of 1,329,749 shares. The stock had previously closed at $5.95.

A number of analysts have issued reports on PETX shares. Zacks Investment Research raised Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $6.50 price target on the stock in a research note on Wednesday, January 2nd. BidaskClub lowered Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 17th. ValuEngine raised Aratana Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, October 22nd. Stifel Nicolaus lowered Aratana Therapeutics from a “buy” rating to a “hold” rating and decreased their price target for the stock from $8.00 to $5.00 in a research note on Friday. Finally, HC Wainwright set a $10.00 price target on Aratana Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 5th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $7.50.

The company has a market cap of $296.12 million, a price-to-earnings ratio of -4.51 and a beta of 1.78. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.17 and a quick ratio of 2.70.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.03. The business had revenue of $21.56 million for the quarter, compared to analyst estimates of $5.70 million. Aratana Therapeutics had a negative return on equity of 15.08% and a negative net margin of 52.94%. Research analysts predict that Aratana Therapeutics Inc will post -0.25 EPS for the current year.

In other news, insider Ernst Heinen sold 19,308 shares of Aratana Therapeutics stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $6.95, for a total value of $134,190.60. Following the transaction, the insider now directly owns 135,694 shares of the company’s stock, valued at approximately $943,073.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Peter Steven St sold 11,513 shares of Aratana Therapeutics stock in a transaction dated Tuesday, October 30th. The shares were sold at an average price of $5.86, for a total value of $67,466.18. Following the completion of the transaction, the insider now directly owns 562,720 shares in the company, valued at $3,297,539.20. The disclosure for this sale can be found here. Insiders sold a total of 77,607 shares of company stock worth $476,116 over the last ninety days. Corporate insiders own 5.30% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hollencrest Capital Management acquired a new position in shares of Aratana Therapeutics in the 4th quarter valued at about $153,000. MetLife Investment Advisors LLC acquired a new position in Aratana Therapeutics during the 3rd quarter worth approximately $215,000. Bank of Montreal Can lifted its position in Aratana Therapeutics by 152.9% during the 3rd quarter. Bank of Montreal Can now owns 51,360 shares of the biopharmaceutical company’s stock worth $301,000 after acquiring an additional 31,053 shares in the last quarter. Acadian Asset Management LLC lifted its position in Aratana Therapeutics by 69.8% during the 3rd quarter. Acadian Asset Management LLC now owns 194,746 shares of the biopharmaceutical company’s stock worth $1,137,000 after acquiring an additional 80,064 shares in the last quarter. Finally, Northern Trust Corp lifted its position in Aratana Therapeutics by 7.2% during the 2nd quarter. Northern Trust Corp now owns 489,766 shares of the biopharmaceutical company’s stock worth $2,082,000 after acquiring an additional 32,773 shares in the last quarter. 67.92% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Aratana Therapeutics (PETX) Stock Price Down 26.6%” was first published by Fairfield Current and is the property of of Fairfield Current. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.fairfieldcurrent.com/news/2019/01/13/aratana-therapeutics-petx-stock-price-down-26-6.html.

Aratana Therapeutics Company Profile (NASDAQ:PETX)

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

See Also: How is a Moving Average Calculated?

Receive News & Ratings for Aratana Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aratana Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Analysts Anticipate Aratana Therapeutics Inc (PETX) to Announce -$0.12 EPS

Finally, Acadian Asset Management LLC boosted its position in shares of Aratana Therapeutics by 69.8% during the 3rd quarter. Acadian Asset …

Aratana Therapeutics logoEquities research analysts expect Aratana Therapeutics Inc (NASDAQ:PETX) to report earnings of ($0.12) per share for the current quarter, according to Zacks. Three analysts have made estimates for Aratana Therapeutics’ earnings. The lowest EPS estimate is ($0.14) and the highest is ($0.10). Aratana Therapeutics reported earnings per share of ($0.19) in the same quarter last year, which would indicate a positive year over year growth rate of 36.8%. The company is scheduled to report its next quarterly earnings results on Tuesday, March 12th.

On average, analysts expect that Aratana Therapeutics will report full-year earnings of ($0.25) per share for the current fiscal year, with EPS estimates ranging from ($0.28) to ($0.23). For the next financial year, analysts expect that the firm will post earnings of ($0.22) per share, with EPS estimates ranging from ($0.32) to ($0.08). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that cover Aratana Therapeutics.

Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.03. The company had revenue of $21.56 million for the quarter, compared to analysts’ expectations of $5.70 million. Aratana Therapeutics had a negative net margin of 52.94% and a negative return on equity of 15.08%.

PETX has been the subject of a number of recent analyst reports. HC Wainwright set a $10.00 target price on Aratana Therapeutics and gave the stock a “buy” rating in a research report on Monday, November 5th. Stifel Nicolaus lowered Aratana Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the stock from $8.00 to $5.00 in a research report on Friday. BidaskClub raised Aratana Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, October 23rd. ValuEngine raised Aratana Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, October 22nd. Finally, TheStreet raised Aratana Therapeutics from a “d” rating to a “c-” rating in a research report on Wednesday, November 21st. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $7.50.

Aratana Therapeutics stock traded down $1.58 during mid-day trading on Friday, reaching $4.37. The stock had a trading volume of 6,796,287 shares, compared to its average volume of 1,329,649. The stock has a market cap of $296.12 million, a price-to-earnings ratio of -4.51 and a beta of 1.78. Aratana Therapeutics has a one year low of $3.67 and a one year high of $7.16. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.17 and a quick ratio of 2.70.

In related news, insider Peter Steven St sold 11,513 shares of the business’s stock in a transaction that occurred on Tuesday, October 30th. The stock was sold at an average price of $5.86, for a total transaction of $67,466.18. Following the completion of the transaction, the insider now directly owns 562,720 shares in the company, valued at approximately $3,297,539.20. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Ernst Heinen sold 19,308 shares of the business’s stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $6.95, for a total value of $134,190.60. Following the transaction, the insider now owns 135,694 shares of the company’s stock, valued at $943,073.30. The disclosure for this sale can be found here. Insiders have sold a total of 77,607 shares of company stock valued at $476,116 in the last ninety days. Insiders own 5.30% of the company’s stock.

Several large investors have recently made changes to their positions in PETX. Hollencrest Capital Management bought a new position in shares of Aratana Therapeutics during the 4th quarter valued at approximately $153,000. American Century Companies Inc. bought a new position in shares of Aratana Therapeutics during the 2nd quarter valued at approximately $195,000. MetLife Investment Advisors LLC bought a new position in shares of Aratana Therapeutics during the 3rd quarter valued at approximately $215,000. Bank of Montreal Can boosted its position in shares of Aratana Therapeutics by 152.9% during the 3rd quarter. Bank of Montreal Can now owns 51,360 shares of the biopharmaceutical company’s stock valued at $301,000 after acquiring an additional 31,053 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its position in shares of Aratana Therapeutics by 69.8% during the 3rd quarter. Acadian Asset Management LLC now owns 194,746 shares of the biopharmaceutical company’s stock valued at $1,137,000 after acquiring an additional 80,064 shares during the last quarter. Institutional investors own 67.92% of the company’s stock.

About Aratana Therapeutics

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

Featured Article: NASDAQ

Get a free copy of the Zacks research report on Aratana Therapeutics (PETX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aratana Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Millennium Management LLC Has $2.27 Million Position in Aratana Therapeutics Inc (PETX)

Millennium Management LLC cut its position in Aratana Therapeutics Inc (NASDAQ:PETX) by 60.3% during the second quarter, according to its most …

Aratana Therapeutics logoMillennium Management LLC cut its position in Aratana Therapeutics Inc (NASDAQ:PETX) by 60.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 534,988 shares of the biopharmaceutical company’s stock after selling 812,987 shares during the period. Millennium Management LLC owned approximately 1.12% of Aratana Therapeutics worth $2,274,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Schwab Charles Investment Management Inc. increased its holdings in shares of Aratana Therapeutics by 23.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 90,100 shares of the biopharmaceutical company’s stock valued at $398,000 after purchasing an additional 17,300 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Aratana Therapeutics by 16.0% in the second quarter. Dimensional Fund Advisors LP now owns 910,328 shares of the biopharmaceutical company’s stock valued at $3,869,000 after purchasing an additional 125,232 shares during the period. Grandeur Peak Global Advisors LLC increased its holdings in shares of Aratana Therapeutics by 29.4% in the second quarter. Grandeur Peak Global Advisors LLC now owns 712,138 shares of the biopharmaceutical company’s stock valued at $3,027,000 after purchasing an additional 161,675 shares during the period. BlackRock Inc. increased its holdings in shares of Aratana Therapeutics by 11.5% in the second quarter. BlackRock Inc. now owns 3,348,240 shares of the biopharmaceutical company’s stock valued at $14,231,000 after purchasing an additional 345,204 shares during the period. Finally, Wells Fargo & Company MN increased its holdings in shares of Aratana Therapeutics by 38.5% in the first quarter. Wells Fargo & Company MN now owns 639,436 shares of the biopharmaceutical company’s stock valued at $2,820,000 after purchasing an additional 177,824 shares during the period. 65.22% of the stock is currently owned by institutional investors and hedge funds.

Several analysts recently commented on the company. Zacks Investment Research lowered Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, November 8th. BidaskClub raised Aratana Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 8th. HC Wainwright set a $10.00 target price on Aratana Therapeutics and gave the stock a “buy” rating in a report on Monday, November 5th. Finally, ValuEngine raised Aratana Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, October 22nd. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $8.15.

In other Aratana Therapeutics news, CEO Peter Steven St sold 75,000 shares of the stock in a transaction that occurred on Friday, September 21st. The stock was sold at an average price of $6.06, for a total transaction of $454,500.00. Following the transaction, the chief executive officer now owns 574,233 shares in the company, valued at $3,479,851.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ernst Heinen sold 19,308 shares of the stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $6.95, for a total value of $134,190.60. Following the transaction, the insider now owns 135,694 shares in the company, valued at approximately $943,073.30. The disclosure for this sale can be found here. Insiders have sold 106,513 shares of company stock worth $660,966 in the last quarter. 5.30% of the stock is currently owned by company insiders.

Aratana Therapeutics stock traded up $0.07 during midday trading on Friday, hitting $6.56. 375,306 shares of the company were exchanged, compared to its average volume of 588,946. The firm has a market cap of $311.68 million, a price-to-earnings ratio of -6.76 and a beta of 1.95. Aratana Therapeutics Inc has a fifty-two week low of $3.67 and a fifty-two week high of $7.28. The company has a quick ratio of 2.70, a current ratio of 3.17 and a debt-to-equity ratio of 0.02.

Aratana Therapeutics (NASDAQ:PETX) last posted its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. The firm had revenue of $21.56 million for the quarter, compared to analyst estimates of $5.70 million. Aratana Therapeutics had a negative return on equity of 15.08% and a negative net margin of 52.94%. Equities analysts expect that Aratana Therapeutics Inc will post -0.25 EPS for the current year.

WARNING: “Millennium Management LLC Has $2.27 Million Position in Aratana Therapeutics Inc (PETX)” was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.baseballdailydigest.com/2018/11/17/millennium-management-llc-sells-812987-shares-of-aratana-therapeutics-inc-petx.html.

Aratana Therapeutics Profile

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

Featured Story: Balanced Fund

Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aratana Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Wells Fargo & Company MN Raises Holdings in Aratana Therapeutics Inc (PETX)

Renaissance Technologies LLC boosted its holdings in Aratana Therapeutics by 55.6% in the 4th quarter. Renaissance Technologies LLC now owns …

Aratana Therapeutics logoWells Fargo & Company MN raised its stake in Aratana Therapeutics Inc (NASDAQ:PETX) by 38.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 639,436 shares of the biopharmaceutical company’s stock after purchasing an additional 177,824 shares during the period. Wells Fargo & Company MN owned approximately 1.39% of Aratana Therapeutics worth $2,820,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of PETX. Geode Capital Management LLC boosted its holdings in Aratana Therapeutics by 7.4% in the 4th quarter. Geode Capital Management LLC now owns 313,626 shares of the biopharmaceutical company’s stock valued at $1,649,000 after purchasing an additional 21,654 shares during the period. Renaissance Technologies LLC boosted its holdings in Aratana Therapeutics by 55.6% in the 4th quarter. Renaissance Technologies LLC now owns 124,800 shares of the biopharmaceutical company’s stock valued at $656,000 after purchasing an additional 44,600 shares during the period. Deutsche Bank AG boosted its holdings in Aratana Therapeutics by 11.2% in the 4th quarter. Deutsche Bank AG now owns 468,114 shares of the biopharmaceutical company’s stock valued at $2,461,000 after purchasing an additional 47,178 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Aratana Therapeutics by 35.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 68,039 shares of the biopharmaceutical company’s stock worth $358,000 after acquiring an additional 17,677 shares during the period. Finally, Ellington Management Group LLC bought a new position in shares of Aratana Therapeutics during the 4th quarter worth about $304,000. 67.04% of the stock is owned by hedge funds and other institutional investors.

A number of research firms have recently commented on PETX. Zacks Investment Research downgraded shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. ValuEngine raised shares of Aratana Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 15th. Credit Suisse Group reaffirmed an “outperform” rating and set a $8.00 price objective (down from $9.00) on shares of Aratana Therapeutics in a report on Friday, March 16th. BidaskClub raised shares of Aratana Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, May 10th. Finally, HC Wainwright set a $10.00 price objective on shares of Aratana Therapeutics and gave the stock a “buy” rating in a report on Monday, May 7th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $8.68.

Aratana Therapeutics opened at $4.49 on Monday, Marketbeat reports. Aratana Therapeutics Inc has a 52 week low of $3.67 and a 52 week high of $7.67. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.37 and a quick ratio of 2.82.

Aratana Therapeutics (NASDAQ:PETX) last announced its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01. The business had revenue of $4.04 million during the quarter, compared to analysts’ expectations of $6.06 million. Aratana Therapeutics had a negative net margin of 168.26% and a negative return on equity of 38.97%. sell-side analysts expect that Aratana Therapeutics Inc will post -0.6 EPS for the current fiscal year.

In related news, insider Peter Steven St sold 11,513 shares of the stock in a transaction dated Monday, April 30th. The shares were sold at an average price of $5.00, for a total transaction of $57,565.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Brent Standridge sold 10,000 shares of the stock in a transaction dated Monday, June 25th. The stock was sold at an average price of $4.56, for a total transaction of $45,600.00. Following the sale, the chief operating officer now owns 99,967 shares of the company’s stock, valued at approximately $455,849.52. The disclosure for this sale can be found here. Company insiders own 5.30% of the company’s stock.

Aratana Therapeutics Profile

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

Want to see what other hedge funds are holding PETX?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aratana Therapeutics Inc (NASDAQ:PETX).

Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aratana Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Aratana Therapeutics Inc (PETX) Holding Reduced by Renaissance Technologies LLC

Renaissance Technologies LLC lowered its position in Aratana Therapeutics Inc (NASDAQ:PETX) by 18.2% during the fourth quarter, according to its …

Renaissance Technologies LLC lowered its position in Aratana Therapeutics Inc (NASDAQ:PETX) by 18.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 87,608 shares of the biopharmaceutical company’s stock after selling 19,492 shares during the period. Renaissance Technologies LLC’s holdings in Aratana Therapeutics were worth $629,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of PETX. DIAM Co. Ltd. acquired a new stake in shares of Aratana Therapeutics during the third quarter worth approximately $747,000. Chicago Equity Partners LLC acquired a new stake in shares of Aratana Therapeutics during the third quarter worth approximately $589,000. Piermont Capital Management Inc. acquired a new stake in shares of Aratana Therapeutics during the third quarter worth approximately $541,000. Capital Fund Management S.A. acquired a new stake in shares of Aratana Therapeutics during the third quarter worth approximately $440,000. Finally, Citadel Advisors LLC raised its stake in shares of Aratana Therapeutics by 82.2% in the third quarter. Citadel Advisors LLC now owns 80,547 shares of the biopharmaceutical company’s stock worth $754,000 after buying an additional 36,348 shares during the period. Institutional investors and hedge funds own 75.44% of the company’s stock.

Shares of Aratana Therapeutics Inc (NASDAQ:PETX) opened at 6.27 on Tuesday. The firm has a 50-day moving average price of $5.55 and a 200-day moving average price of $7.02. Aratana Therapeutics Inc has a 52-week low of $4.97 and a 52-week high of $10.73. The stock’s market capitalization is $234.26 million.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings results on Monday, March 13th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.42) by $0.22. The firm had revenue of $0.29 million for the quarter, compared to the consensus estimate of $0.80 million. Aratana Therapeutics had a negative net margin of 60.32% and a negative return on equity of 19.87%. Aratana Therapeutics’s quarterly revenue was up 363.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.37) earnings per share. On average, analysts predict that Aratana Therapeutics Inc will post ($1.29) EPS for the current year.

A number of analysts have issued reports on PETX shares. Jefferies Group LLC decreased their target price on Aratana Therapeutics to $8.00 in a research report on Thursday, March 16th. Zacks Investment Research raised Aratana Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 1st. William Blair reissued an “outperform” rating on shares of Aratana Therapeutics in a research report on Thursday, February 9th. Finally, Stifel Nicolaus downgraded Aratana Therapeutics from a “buy” rating to a “hold” rating and set a $8.00 target price for the company. in a research report on Monday, February 6th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $10.25.

In other news, insider Peter Steven St sold 50,000 shares of the stock in a transaction on Monday, April 17th. The stock was sold at an average price of $5.54, for a total transaction of $277,000.00. Following the transaction, the insider now directly owns 582,693 shares of the company’s stock, valued at approximately $3,228,119.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 6.70% of the stock is owned by corporate insiders.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Want to see what other hedge funds are holding PETX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aratana Therapeutics Inc (NASDAQ:PETX).

Related Posts:

  • No Related Posts